Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27673825 | 1.00 | CYP1A2 (0.33) | CYP1A2SMN1; SMN2NPSR1KDM4EALDH1A1 | |
| SCHEMBL13655382 | 0.84 | NPSR1 (0.31) | NPSR1 | |
| SCHEMBL27674176 | 0.82 | SMN1; SMN2 (0.39) | SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL331614 | 0.82 | SMN1; SMN2 (0.39) | SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL331349 | 0.78 | ALDH1A1 (0.36) | CYP1A2SMN1; SMN2NPSR1KDM4EALDH1A1 | |
| SCHEMBL8296737 | 0.75 | POLB (0.37) | SMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL7002826 | 0.74 | CYP1A2 (0.60) | CYP1A2SMN1; SMN2KDM4EALDH1A1HPGD | |
| SCHEMBL333012 | 0.74 | ALDH1A1 (0.33) | CYP1A2SMN1; SMN2NPSR1KDM4EALDH1A1 | |
| SCHEMBL14113963 | 0.74 | CYP1A2 (0.32) | CYP1A2SMN1; SMN2NPSR1KDM4EALDH1A1 | |
| SCHEMBL331072 | 0.74 | CYP1A2 (0.32) | CYP1A2SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097621-B2 | Pyrazolo[4,3-d]pyrimidines as phosphodiesterase inhibitors | PFIZER INC. (US) | 2012-01-17 | — | — | US | disclosed |
| US-8097621-B2 | Pyrazolo[4,3-d]pyrimidines as phosphodiesterase inhibitors | PFIZER INC. (US) | 2012-01-17 | — | — | US | disclosed |
| US-8097621-B2 | Pyrazolo[4,3-d]pyrimidines as phosphodiesterase inhibitors | PFIZER INC. (US) | 2012-01-17 | — | — | US | disclosed |
| CN-1882591-B | 5, 7-diaminopyrazolo [4,3-d ] pyrimidines with PDE-5 inhibiting activity | PFIZER LTD | 2011-08-10 | — | — | CN | disclosed |
| CN-101362764-B | 5,7-diaminopyrazolo '4,3-d!pyrimidines with PDE-5 inhibiting activity | PFIZER | 2011-04-20 | — | — | CN | disclosed |
| CN-101362765-B | 5,7-diaminopyrazolo '4,3-d-pyrimidines with PDE-5 inhibiting activity | PFIZER | 2011-02-02 | — | — | CN | disclosed |
| EP-1689751-B1 | 5,7-DIAMINOPYRAZOLO[4,3-D]PYRIMIDINES WITH PDE-5 INHIBITING ACTIVITY | PFIZER LTD (GB) | 2010-10-20 | — | — | EP | disclosed |
| CN-101647802-A | 5,7-diaminopyrazolo [4,3-d] pyrimidines with pde-5 inhibiting activity and composition thereof | PFIZER LTD US | 2010-02-17 | — | — | CN | disclosed |
| US-20090247539-A1 | Novel Pharmaceuticals | PFIZER INC | 2009-10-01 | — | — | US | disclosed |
| US-20090247539-A1 | Novel Pharmaceuticals | PFIZER INC | 2009-10-01 | — | — | US | disclosed |
| US-7572799-B2 | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors | PFIZER INC (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572799-B2 | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors | PFIZER INC (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572799-B2 | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors | PFIZER INC (US) | 2009-08-11 | — | — | US | disclosed |
| CN-101362765-A | 5,7-diaminopyrazolo '4,3-d!pyrimidines with PDE-5 inhibiting activity | PFIZER (US) | 2009-02-11 | — | — | CN | disclosed |
| CN-101362764-A | 5,7-diaminopyrazolo '4,3-d!pyrimidines with PDE-5 inhibiting activity | PFIZER (US) | 2009-02-11 | — | — | CN | disclosed |
| CN-1882591-A | 5, 7-diaminopyrazolo [4, 3-d ] pyrimidines with PDE-5 inhibiting activity | PFIZER LTD (US) | 2006-12-20 | — | — | CN | disclosed |
| EP-1689751-A1 | 5,7-DIAMINOPYRAZOLO¬4,3-D|PYRIMIDINES WITH PDE-5 INHIBITING ACTIVITY | Pfizer Limited (GB) | 2006-08-16 | — | — | EP | disclosed |
| US-20050245544-A1 | Novel pharmaceuticals | AMPLIFIED PROTEOMICS INC. | 2005-11-03 | — | — | US | disclosed |
| WO-2005049616-A1 | 5,7-DIAMINOPYRAZOLO [4,3-d] PYRIMIDINES WITH PDE-5 INHIBITING ACTIVITY | PFIZER LIMITED (GB) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005049616-A1 | 5,7-DIAMINOPYRAZOLO [4,3-d] PYRIMIDINES WITH PDE-5 INHIBITING ACTIVITY | PFIZER LIMITED (GB) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245544-A1 | Novel pharmaceuticals | ABCB11, PCSK9, SLC10A1 | CYP1A2 86/4885SMN1; SMN2 2626/4885NPSR1 99/4885 |
| US-20090247539-A1 | Novel Pharmaceuticals | ABCB11, PCSK9, SLC10A1 | CYP1A2 86/4885SMN1; SMN2 2626/4885NPSR1 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.